Literatur
-
1 Anthenelli R. Rimonabant as an aid to smoking cessation in smokers motivated to quit. American College of Cardiology - 2004 Annual Scientific Meeting, 09 März 2004. New Orleans, USA 2004
-
2
Ballantyne C M, Houri J, Notarbartolo A, Melani L, Lipka L J, Suresh R, Sun S, LeBeaut A P, Sager P T, Veltri E P. for Ezetimibe Study Group .
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Circulation.
2003;
107
2409-2415
-
3
Barnett A H.
Exubera inhaled insulin: a review.
Int J Clin Pract.
2004;
58
394-401
-
4
Bauer K A, Eriksson B I, Lassen M R, Turpie A G.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
N Engl J Med.
2001;
345
1305-1310
-
5
Bischoff A.
Cetuximab. Ein Antikörper gegen mehrere Tumorentitäten.
Dtsch Ärztebl.
2004;
101
2406
-
6
Black D M, Greenspan S L, Ensrud K E, Palermo L, McGowan J A, Lang T F, Garnero P, Bouxsein M L, Bilezikian J P, Rosen C J. PaTH Study Investigators .
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
N Engl J Med.
2003;
349
1207-1215
-
7
Body J J, Gaich G A, Scheele W H, Kulkarni P M, Miller P D, Peretz A, Dore R K, Correa-Rotter R, Papaioannou A, Cumming D C, Hodsman A B.
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1 - 34)] with alendronate in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab.
2002;
87
4528-4535
-
8
Buller H R, Davidson B L, Decousus H, Gallus A, Gent M, Piovella F, Prins M H, Raskob G, Segers A E, Cariou R, Leeuwenkamp O, Lensing A W. Matisse Investigators .
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Ann Intern Med.
2004;
140
867-873
-
9
Cleland J G, Ghosh J, Freemantle N, Kaye G C, Nasir M, Clark A L, Coletta A P.
Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.
Eur J Heart Fail.
2004;
6
501-508
-
10
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Engl J Med.
2004;
351
337-345
-
11 Danzon P, Furukawa M. Prices and availability of pharmaceuticals: Evidence from nine countries. In: Health Affairs Web Exclusive 2003
-
12 Despres J P. Weight reducing and metabolic effects of rimonabant in overweight/obese patients with untreated dyslipidemia. American College of Cardiology - 2004 Annual Scientific Meeting, 09 März 2004. New Orleans, USA 2004
-
13
Eriksson B I, Bauer K A, Lassen M R, Turpie A G.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
N Engl J Med.
2001;
345
1298-1304
-
14
Fernandez J R, Allison D B.
Rimonabant Sanofi-Synthelabo.
Curr Opin Investig Drugs.
2004;
5
430-435
-
15 Fricke U, Schwabe U. Neue Arzneimittel. Springer-Verlag Berlin Heidelberg In: Schwabe U, Paffrath D (Hrsg.). Arzneiverordnungs-Report 2004 37-75
-
16 Fricke U. Neue Arzneimittel - Ein Überblick. Therapiesymposium 2003. Arzneimittelkommission der deutschen Ärzteschaft, Bad Nauheim 2003
-
17
Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T.
Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
Diabetes Care.
2000;
23
1343-1347
-
18
Khorana A A, Ryan C K, Eberly S, Sahasrabudhe D M, James P, Wilmot J P.
EGFR expression and survival in stage II, III and IV colon cancer.
Proc Am Soc Clin Oncol.
2003;
22
317
-
19
Kirkham T C, Williams C M.
Endogenous cannabinoids and appetite.
Nutr Res Rev.
2001;
14
65-86
-
20
Knopp R H, Dujovne C A, Le B eaut A, Lipka L J, Suresh R, Veltri E P. for Ezetimibe Study Group .
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.
Int J Clin Pract.
2003;
57
363-368
-
21
Lassen M R, Bauer K A, Eriksson B I, Turpie A G.
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Lancet.
2002;
359
1715-1720
-
22
Neer R M, Arnaud C D, Zanchetta J R, Prince R, Gaich G A, Reginster J Y, Hodsman A B, Eriksen E F, Ish-Shalom S, Genant H K, Wang O, Mitlak B H.
Effect of parathyroid hormone (1 - 34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med.
2001;
344
1434-1441
-
23
Rosenstock J, Cappelleri J C, Bolinder B, Gerber R A.
Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.
Diabetes Care.
2004;
27
1318-1323
-
24
Royle P, Waugh N, McAuley L, McIntyre L, Thomas S.
Inhaled insulin in diabetes mellitus.
Cochrane Database Syst Rev.
2003;
CD003890
-
25
Taylor D.
Fewer new drugs from the pharmaceutical industry.
Brit Med J.
2003;
326
408-409
-
26
Turpie A G, Bauer K A, Eriksson B I, Lassen M R.
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Arch Intern Med.
2002;
162
1833-1840
-
27
Turpie A G, Bauer K A, Eriksson B I, Lassen M R.
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Lancet.
2002;
359
1721-1726
-
28
Turpie A G, Gallus A S, Hoek J A.
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
N Engl J Med.
2001;
344
619-625
-
29 Van Gaal L F. Effect of rimonabant on weight reduction and metabolic risk factors. European Society of Cardiology - 2004 Annual Meeting, 28 August - 01. September 2004. München, Deutschland 2004
-
30
Vanhoefer U.
Neue molekulare Ansätze in der Therapie des fortgeschrittenen kolorektalen Karzinoms.
Onkologie.
2003;
26
(Suppl 7)
70-74
-
31
Vetter C.
Diabetes mellitus. Wenn Insulin inhaliert wird.
Dtsch Ärztebl.
2004;
101
1313
-
32
Walenga J M, Jeske W P, Samama M M, Frapaise F X, Bick R L, Fareed J.
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
Expert Opin Investig Drugs.
2002;
11
397-407
Dr. E. A. Müller
Institut für Klinische Pharmakologie, Medizinische Fakultät, Technische Universität
Fiedlerstraße 27
01307 Dresden
Phone: 0351/4582815
Fax: 0351/4584341
Email: wilhelm.kirch@mailbox.tu-dresden.de
